Focused On-demand Library for Sushi repeat-containing protein SRPX2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O60687

UPID:

SRPX2_HUMAN

Alternative names:

Sushi-repeat protein upregulated in leukemia

Alternative UPACC:

O60687; B3KQT3; Q8WW85

Background:

The Sushi repeat-containing protein SRPX2, also known as Sushi-repeat protein upregulated in leukemia, plays a pivotal role in various biological processes. It acts as a ligand for the urokinase plasminogen activator surface receptor, contributing to angiogenesis through endothelial cell migration and vascular network formation. SRPX2 is also involved in cellular migration, adhesion, and increases the phosphorylation levels of FAK. Furthermore, it interacts with HGF to enhance mitogenic activity and promotes synapse formation, indicating a significant role in the perisylvian region crucial for language and cognitive development.

Therapeutic significance:

SRPX2's involvement in Rolandic epilepsy, impaired intellectual development, and speech dyspraxia, X-linked, underscores its therapeutic potential. Understanding the role of SRPX2 could open doors to potential therapeutic strategies for these conditions, highlighting the importance of targeted research in uncovering novel treatment avenues.